Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Baltimore, Maryland

This page shows live ClinicalTrials.gov search results for Baltimore, Maryland, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
13749
Shown on this page
12
Current sort
Recently updated
Location scope
Baltimore, MD
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Baltimore, Maryland. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 745–756 of 13,749 matching trials in Baltimore, MD.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Baltimore

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting No phase listed Observational

Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma

NCT06463262
View directory record Official record
Conditions
Chordoma of Spine, Chordoma of Skull Base, Chordoma of Sacrum
Interventions
ctDNA
Diagnostic Test
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
40 participants
Timeline
2024 – 2031
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST
Completed Phase 3 Interventional Results available

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

NCT04770545
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
PEGCETACOPLAN (APL-2)
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
99
States / cities
Phoenix, Arizona • Bakersfield, California • Campbell, California + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Vasopressin and Pain Perception in the Brain

NCT03446456
View directory record Official record
Conditions
Acute Pain
Interventions
Arginine vasopressin, Saline, Observational learning, fMRI data aquisition
Drug · Other · Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST
Active, not recruiting Phase 1 Interventional Results available

Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma

NCT04658147
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Relatlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST
Recruiting Phase 4 Interventional

Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food Allergy

NCT07845552
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST
Completed No phase listed Observational

Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population

NCT07382076
View directory record Official record
Conditions
Activated Clotting Time
Interventions
Blood draw
Diagnostic Test
Lead sponsor
Abbott Point of Care
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Chandler, Arizona • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST
Recruiting Early Phase 1 Interventional

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

NCT04139304
View directory record Official record
Conditions
Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Daratumumab, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Prednisone, Vincristine, Vincristine Sulfate
Drug · Biological
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
9
States / cities
Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST
Recruiting Phase 3 Interventional

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Trastuzumab Deruxtecan, Bevacizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older · Female only
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
33
States / cities
Burbank, California • La Jolla, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST
Recruiting Phase 2 Interventional

Transition to KPL-387 Monotherapy Dosing & Administration Study

NCT07288216
View directory record Official record
Conditions
Recurrent Pericarditis, Heart Diseases, Pericarditis
Interventions
KPL-387
Drug
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST
Not yet recruiting Phase 2 Interventional

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events

NCT07836101
View directory record Official record
Conditions
Any Advanced Solid Tumors
Interventions
Sarilumab, ICI Therapy
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

NCT04713046
View directory record Official record
Conditions
HPV 16+ Recurrent or Metastatic Cancer
Interventions
CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16, Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST
Recruiting Phase 3 Interventional

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Belumosudil, Azithromycin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 15, 2026, 10:07 AM EST